A potential new approach for treating systemic sclerosis: Dedifferentiation of SSc fibroblasts and change in the microenvironment by blocking store-operated Ca(2+) entry

Transforming growth factor-β (TGF-β) is an important target for treating systemic sclerosis (SSc). However, our study revealed three levels of TGF-β1 expression in SSc patients, indicating that inhibiting TGF-β is not sufficient to treat SSc. A previous clinical trial also displayed disappointing re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ching-Ying, Hsu, Wen-Li, Tsai, Ming-Hsien, Chai, Chee-Yin, Yen, Chia-Jung, Chen, Chu-Huang, Lu, Jian-He, Yu, Hsin-Su, Yoshioka, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417669/
https://www.ncbi.nlm.nih.gov/pubmed/30870448
http://dx.doi.org/10.1371/journal.pone.0213400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417669/
https://www.ncbi.nlm.nih.gov/pubmed/30870448
http://dx.doi.org/10.1371/journal.pone.0213400

Ejemplares similares